Dr.ย Galย Markel
MD, PhD
Head, Ella Lemelbaum Institute for Immuno-Oncology
corporate_fareSheba Medical Center, Tel HaShomer, Ramat Gan, Israel
Gal Markel
MD, PhD
Prof. Gal Markel is one of Israel's foremost experts in melanoma and cancer immunotherapy, leading the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center โ one of the most recognised immuno-oncology centres globally. He is a physician-scientist whose career has bridged laboratory tumour immunology with clinical practice across more than two decades.
Prof. Markel's clinical and research work has focused on advancing outcomes for patients with advanced melanoma and solid tumours through personalised immunotherapy, adoptive cell therapy, and translational research. He is internationally known for his involvement in tumour-infiltrating lymphocyte therapy programmes at Sheba and for his academic contributions in melanoma biology, immune escape mechanisms, and immunotherapy resistance. His research has spanned immune checkpoint inhibitors, microbiome-based strategies to improve immunotherapy response, and novel cellular approaches including TIL-based treatment. He holds academic affiliations with Tel Aviv University and trained at the Hebrew University of Jerusalem and the Weizmann Institute of Science.
CancerFax can coordinate medical record review and consultation support for international patients seeking expert opinion from Prof. Markel's team at Sheba Medical Center, subject to case acceptance and hospital availability.
Why Consider Prof. Gal Markel?
Prof. Gal Markel combines deep clinical oncology expertise with internationally recognised research in melanoma immunotherapy and advanced cellular therapies. For patients with advanced or treatment-resistant melanoma, he represents access to Israel's most sophisticated TIL therapy and immuno-oncology programme.
Areas of Specialisation
Melanoma, TIL therapy, immune checkpoint treatment, and translational tumour immunology
Prof. Gal Markel specialises in advanced melanoma treatment and personalised immunotherapy, with particular expertise in tumour-infiltrating lymphocyte therapy, immune checkpoint inhibitors, and the science of immunotherapy resistance.
Melanoma & Skin Cancer
Advanced and metastatic melanoma management with both systemic immunotherapy and cellular therapy approaches.
- arrow_rightMetastatic and unresectable melanoma treatment planning
- arrow_rightSequencing of immunotherapy and targeted therapy for BRAF-mutated disease
- arrow_rightManagement of melanoma progressing after PD-1 or CTLA-4 therapy
- arrow_rightMerkel cell carcinoma and squamous cell carcinoma of the skin
- arrow_rightBasal cell carcinoma and other advanced cutaneous tumours
Tumour-Infiltrating Lymphocyte Therapy
TIL therapy involves isolating immune cells from the patient's own tumour, expanding them in the laboratory, and reinfusing them to target cancer โ an advanced cellular approach offered at Sheba's Ella Lemelbaum Institute.
- arrow_rightTIL harvest, expansion and reinfusion for advanced melanoma
- arrow_rightEligibility evaluation for patients refractory to prior immunotherapy
- arrow_rightCoordination with Sheba's dedicated cell therapy infrastructure
- arrow_rightPersonalised immune cell-based treatment strategies
- arrow_rightIntegration with checkpoint inhibitor pre-conditioning regimens
Immune Checkpoint Therapy
Clinical management with PD-1, PD-L1 and CTLA-4 inhibitors for melanoma and selected solid tumours, including combination regimens and management of immune-related adverse events.
- arrow_rightPembrolizumab, nivolumab and ipilimumab-based regimens
- arrow_rightCombination immunotherapy strategies for advanced disease
- arrow_rightManagement of immune-related toxicity and treatment response assessment
Translational Tumour Immunology
Research-driven clinical approach exploring immune escape, tumour microenvironment, and novel strategies to restore immunotherapy sensitivity.
- arrow_rightMechanisms of tumour immune escape and PD-1 resistance
- arrow_rightMicrobiome-based strategies to modulate immunotherapy response
- arrow_rightNovel cellular and immune approaches in translational studies
Procedures & Clinical Services
Treatment approaches and clinical services available through Sheba's immuno-oncology programme
Prof. Markel's clinical practice at Sheba Medical Center encompasses advanced systemic and cellular immunotherapy, treatment planning for complex melanoma cases, and expert second opinions for patients who have exhausted standard treatment pathways.
Medical Oncology โ Melanoma
Medical OncologyComprehensive treatment planning and systemic therapy management for advanced and metastatic melanoma.
TIL Therapy & Adoptive Cell Therapy
Targeted TherapyAdvanced cellular therapy for eligible patients with advanced melanoma, including TIL harvest, ex-vivo expansion and reinfusion.
Complex & Refractory Melanoma
Complex DiseaseMultidisciplinary evaluation and personalised strategy for patients with treatment-resistant or molecularly complex disease.
Second Opinion โ Melanoma & Immunotherapy
Second OpinionExpert review of treatment plans for advanced melanoma, solid tumours, and immunotherapy-related decisions from an internationally recognised immuno-oncology specialist.
Research & Publications
Melanoma immunology, TIL therapy and translational immuno-oncology
Prof. Gal Markel has a substantial publication record in melanoma biology, tumour immunology and cellular therapy. His research spans immune escape mechanisms, checkpoint inhibitor resistance, adoptive cell therapy and novel strategies including microbiome modulation to improve immunotherapy outcomes.
Prof. Markel's peer-reviewed publications in melanoma immunology and TIL therapy are available via PubMed and Google Scholar. A curated publication list can be provided on request through CancerFax.
Education & Training
Prof. Gal Markel completed his medical and doctoral training at two of Israel's leading academic institutions โ the Hebrew University of Jerusalem and the Weizmann Institute of Science โ building a strong foundation in both clinical medicine and translational immunology.
Clinical Experience
Prof. Gal Markel has dedicated over two decades to advancing melanoma treatment and cancer immunotherapy in Israel and internationally. He leads the Ella Lemelbaum Institute for Immuno-Oncology at Sheba Medical Center, one of the most advanced immuno-oncology programmes globally, and has also held a senior leadership role at the Davidoff Comprehensive Cancer Center at Rabin Medical Center.
Languages & International
Prof. Gal Markel consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients where required.
CancerFax can coordinate professional medical interpreter support for international patients consulting in other languages.
How CancerFax Helps You Access Dr. Gal Markel
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Gal Markel's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Gal Markel's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Gal Markel before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Gal Markel's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Gal Markel's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Gal Markel's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Gal Markel
Prof. Gal Markel is a leading melanoma and cancer immunotherapy specialist based at Sheba Medical Center in Tel HaShomer, Israel. He heads the Ella Lemelbaum Institute for Immuno-Oncology at Sheba โ one of the most internationally recognised immuno-oncology programmes โ and is widely known for his expertise in tumour-infiltrating lymphocyte therapy, immune checkpoint treatment, and translational melanoma research.
Tumour-infiltrating lymphocyte therapy, or TIL therapy, is an advanced cellular treatment in which immune cells are isolated from the patient's own tumour, expanded in the laboratory, and reinfused to target cancer cells. The Ella Lemelbaum Institute at Sheba Medical Center has one of the most established TIL therapy programmes globally. CancerFax can assist international patients in understanding eligibility and coordinating case submission to the programme, subject to medical review and hospital acceptance.
Prof. Markel's primary expertise is in advanced and metastatic melanoma, high-risk skin cancers including Merkel cell carcinoma and squamous cell carcinoma of the skin, and selected solid tumours considered for immunotherapy. He has particular experience in patients whose disease has progressed on PD-1, CTLA-4, or BRAF-targeted therapy.
Sheba Medical Center has a well-established international patient programme. CancerFax can coordinate medical record review, case preparation, and consultation requests for international patients seeking an expert opinion from Prof. Markel or the Ella Lemelbaum Institute's immuno-oncology team. Acceptance is subject to case review and hospital availability.
International patients can submit their medical records through CancerFax, including biopsy and pathology reports, PET-CT or CT/MRI imaging, mutation or NGS reports, and prior treatment history. The CancerFax team will review the documents, prepare a structured case summary, and coordinate the next steps with Sheba Medical Center, subject to availability and clinical eligibility.
Prof. Markel has an active research background in melanoma immunotherapy, and the Ella Lemelbaum Institute at Sheba Medical Center runs clinical studies in immuno-oncology and TIL-based treatment. Whether a specific patient qualifies for an ongoing trial depends on the clinical protocol and eligibility criteria. CancerFax can assist in submitting case details for evaluation.
Connect with Gal Markel Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.